Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells

Molecular and Cellular Proteomics

Volumn 14, Issue 2, 2015, Pages 316-328

  Ren, Xiaoqing ^a   Bai, Xue ^a   Zhang, Xuefei ^a   Li, Zheyi ^a   Tang, Lingfang ^a   Zhao, Xuyang ^a,b   Li, Zeyang ^a   Ren, Yanfei ^a   Wei, Shicheng ^a,c   Wang, Qingsong ^a   Liu, Cong ^d   Ji, Jianguo ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 137; RESVERATROL; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, MOUSE; MESSENGER RNA; MIRN137 MICRORNA, MOUSE; NUCLEAR PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEOME; STILBENE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CLU GENE; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE REPRESSION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LONG TERM SURVIVAL; MOUSE; NEUROBLASTOMA CELL; NGFR GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; RNA INTERFERENCE; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; BIOLOGY; CELL NUCLEUS; DRUG EFFECTS; GENE SILENCING; GENETICS; HEK293 CELL LINE; METABOLISM; NEUROBLASTOMA; PATHOLOGY; PROTEIN SYNTHESIS; REPRODUCIBILITY; TIME; TUMOR CELL LINE;

RICE STRIPE VIRUS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; COMPUTATIONAL BIOLOGY; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; ISOTOPE LABELING; MICE; MICRORNAS; NEUROBLASTOMA; NUCLEAR PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BIOSYNTHESIS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; STILBENES; TIME FACTORS;

EID: 84921922395     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M114.041905     Document Type: Article

References (49)

1. Park, J. R., Eggert, A., and Caron, H. (2010) Neuroblastoma: biology, prognosis, and treatment. Hematol. Oncol. Clin. North Am. 24, 65-86
2. Goldsby, R. E., and Matthay, K. K. (2004) Neuroblastoma: evolving therapies for a disease with many faces. Paediatr. drugs 6, 107-122
3. De Bernardi, B., Nicolas, B., Boni, L., Indolfi, P., Carli, M., Cordero Di Montezemolo, L., Donfrancesco, A., Pession, A., Provenzi, M., di Cataldo, A., Rizzo, A., Tonini, G. P., Dallorso, S., Conte, M., Gambini, C., Garaventa, A., Bonetti, F., Zanazzo, A., D'Angelo, P., Bruzzi, P., and Italian Co-Operative Group for, N. (2003) Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J. Clin. Oncol. 21, 1592-1601
4. Tang, S. Q., Huang, D. S., Wang, J. W., Zhang, X. F., Liu, L. Z., Yu, F., and Yang, G. (2004) Treatment of high-risk neuroblastoma with intensive chemotherapy, autologous peripheral blood stem cell transplantation, and 13-cis-retinoic acid. Zhonghua er ke za zhi 42, 486-489
5. Huang, M., and Weiss, W. A. (2013) Neuroblastoma and MYCN. Cold Spring Harb. Perspect. Med. 3, a014415
6. Maris, J. M., White, P. S., Beltinger, C. P., Sulman, E. P., Castleberry, R. P., Shuster, J. J., Look, A. T., and Brodeur, G. M. (1995) Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res. 55, 4664-4669
7. Look, A. T., Hayes, F. A., Shuster, J. J., Douglass, E. C., Castleberry, R. P., Bowman, L. C., Smith, E. I., and Brodeur, G. M. (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 9, 581-591
8. Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., and Brodeur, G. M. (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J. Med. 328, 847-854
9. Tang, X. X., Zhao, H., Robinson, M. E., Cohen, B., Cnaan, A., London, W., Cohn, S. L., Cheung, N. K., Brodeur, G. M., Evans, A. E., and Ikegaki, N. (2000) Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc. Natl. Acad. Sci. U.S.A. 97, 10936-10941
10. Alimova, I., Venkataraman, S., Harris, P., Marquez, V. E., Northcott, P. A., Dubuc, A., Taylor, M. D., Foreman, N. K., and Vibhakar, R. (2012) Targeting the enhancer of zeste homolog 2 in medulloblastoma. Int. J. Cancer 131, 1800-1809
11. Wang, C., Liu, Z., Woo, C. W., Li, Z., Wang, L., Wei, J. S., Marquez, V. E., Bates, S. E., Jin, Q., Khan, J., Ge, K., and Thiele, C. J. (2012) EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res. 72, 315-324
12. Zhi, F., Wang, R., Wang, Q., Xue, L., Deng, D., Wang, S., and Yang, Y. (2014) MicroRNAs in Neuroblastoma: small-sized players with a large impact. Neurochem. Res. 39, 613-623
13. Althoff, K., Beckers, A., Odersky, A., Mestdagh, P., Koster, J., Bray, I. M., Bryan, K., Vandesompele, J., Speleman, F., Stallings, R. L., Schramm, A., Eggert, A., Sprussel, A., and Schulte, J. H. (2013) MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int. J. Cancer 133, 1064-1073
14. Szulwach, K. E., Li, X., Smrt, R. D., Li, Y., Luo, Y., Li, L., Santistevan, N. J., Li, W., Zhao, X., and Jin, P. (2010) Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J. Cell Biol. 189, 127-141
15. Baur, J. A., and Sinclair, D. A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5, 493-506
16. Tang, H. Y., Shih, A., Cao, H. J., Davis, F. B., Davis, P. J., and Lin, H. Y. (2006) Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 5, 2034-2042
17. Chen, Q. R., Song, Y. K., Yu, L. R., Wei, J. S., Chung, J. Y., Hewitt, S. M., Veenstra, T. D., and Khan, J. (2010) Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma. J. Proteome Res. 9, 373-382
18. Wang, Q., Xu, J., Rottinghaus, G. E., Simonyi, A., Lubahn, D., Sun, G. Y., and Sun, A. Y. (2002) Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 958, 439-447
19. Russo, A., Palumbo, M., Aliano, C., Lempereur, L., Scoto, G., and Renis, M. (2003) Red wine micronutrients as protective agents in Alzheimer-like induced insult. Life Sci. 72, 2369-2379
20. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220
21. Ragione, F. D., Cucciolla, V., Borriello, A., Pietra, V. D., Racioppi, L., Soldati, G., Manna, C., Galletti, P., and Zappia, V. (1998) Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem. Biophys. Res. Commun. 250, 53-58
22. Hsieh, T. C., and Wu, J. M. (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 249, 109-115
23. Holmes-McNary, M., and Baldwin, A. S., Jr. (2000) Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res. 60, 3477-3483
24. Henderson, M. J., Haber, M., Porro, A., Munoz, M. A., Iraci, N., Xue, C., Murray, J., Flemming, C. L., Smith, J., Fletcher, J. I., Gherardi, S., Kwek, C. K., Russell, A. J., Valli, E., London, W. B., Buxton, A. B., Ashton, L. J., Sartorelli, A. C., Cohn, S. L., Schwab, M., Marshall, G. M., Perini, G., and Norris, M. D. (2011) ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J. Natl. Cancer Inst. 103, 1236-1251
25. Jeison, M., Ash, S., Halevy-Berko, G., Mardoukh, J., Luria, D., Avigad, S., Feinberg-Gorenshtein, G., Goshen, Y., Hertzel, G., Kapelushnik, J., Ben Barak, A., Attias, D., Steinberg, R., Stein, J., Stark, B., and Yaniv, I. (2010) 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics. Am. J. Pathol. 176, 2616-2625
26. Ong, S. E., and Mann, M. (2005) Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 1, 252-262
27. Phanstiel, D., Brumbaugh, J., Berggren, W. T., Conard, K., Feng, X., Levenstein, M. E., McAlister, G. C., Thomson, J. A., and Coon, J. J. (2008) Mass spectrometry identifies and quantifies 74 unique histone H4 isoforms in differentiating human embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 105, 4093-4098
28. Cox, J., Matic, I., Hilger, M., Nagaraj, N., Selbach, M., Olsen, J. V., and Mann, M. (2009) A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat. Protoc. 4, 698-705
29. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372
30. Cox, J., and Mann, M. (2012) 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary highthroughput data. BMC Bioinformatics 16, S12
31. Carmona-Saez, P., Chagoyen, M., Tirado, F., Carazo, J. M., and Pascual-Montano, A. (2007) GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 8, R3
32. Jhumka, Z., Pervaiz, S., and Clement, M. V. (2009) Resveratrol regulates the expression of NHE-1 by repressing its promoter activity: critical involvement of intracellular H2O2 and caspases 3 and 6 in the absence of cell death. Int. J. Biochem. Cell Biol. 41, 945-956
33. Lee, S. C., Chan, J., Clement, M. V., and Pervaiz, S. (2006) Functional proteomics of resveratrol-induced colon cancer cell apoptosis: caspase-6-mediated cleavage of lamin A is a major signaling loop. Proteomics 6, 2386-2394
34. Allen, R. T., Hunter, W. J., 3rd, and Agrawal, D. K. (1997) Morphological and biochemical characterization and analysis of apoptosis. J. Pharmacol. Toxicol. Methods 37, 215-228
35. Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K., Tan, P. B., Liu, E. T., and Yu, Q. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063
36. Gu, Z., Jiang, J., Tan, W., Xia, Y., Cao, H., Meng, Y., Da, Z., Liu, H., and Cheng, C. (2013) p53/p21 Pathway involved in mediating cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Clin. Dev. Immunol. 2013:134243
37. Coufal, J., Jagelska, E. B., Liao, J. C., and Brazda, V. (2013) Preferential binding of p53 tumor suppressor to p21 promoter sites that contain inverted repeats capable of forming cruciform structure. Biochem. Biophys. Res. Commun. 441, 83-88
38. Nashir Udden, S. M., Morita-Fujimura, Y., Satake, M., and Ikawa, S. (2013) c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage. Cell. Signal. 26, 444-452
39. Benson, E. K., Mungamuri, S. K., Attie, O., Kracikova, M., Sachidanandam, R., Manfredi, J. J., and Aaronson, S. A. (2013) p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. Oncogene. 33, 3959-3969
40. Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozbun, L., Armaiz-Pena, G. N., Hu, W., Stone, R. L., Munkarah, A., Ravoori, M. K., Shahzad, M. M., Lee, J. W., Mora, E., Langley, R. R., Carroll, A. R., Matsuo, K., Spannuth, W. A., Schmandt, R., Jennings, N. B., Goodman, B. W., Jaffe, R. B., Nick, A. M., Kim, H. S., Guven, E. O., Chen, Y. H., Li, L. Y., Hsu, M. C., Coleman, R. L., Calin, G. A., Denkbas, E. B., Lim, J. Y., Lee, J. S., Kundra, V., Birrer, M. J., Hung, M. C., Lopez-Berestein, G., and Sood, A. K. (2010) Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185-197
41. Fujii, S., Tokita, K., Wada, N., Ito, K., Yamauchi, C., Ito, Y., and Ochiai, A. (2011) MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 30, 4118-4128
42. Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G., Otte, A. P., Rubin, M. A., and Chinnaiyan, A. M. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629
43. Tsang, D. P., and Cheng, A. S. (2011) Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J. Gastroenterol. Hepatol. 26, 19-27
44. Sellers, W. R., and Loda, M. (2002) The EZH2 polycomb transcriptional repressor-A marker or mover of metastatic prostate cancer? Cancer Cell 2, 349-350
45. Lee, S. T., Li, Z., Wu, Z., Aau, M., Guan, P., Karuturi, R. K., Liou, Y. C., and Yu, Q. (2011) Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol. Cell 43, 798-810
46. Yamagishi, M., Nakano, K., Miyake, A., Yamochi, T., Kagami, Y., Tsutsumi, A., Matsuda, Y., Sato-Otsubo, A., Muto, S., Utsunomiya, A., Yamaguchi, K., Uchimaru, K., Ogawa, S., and Watanabe, T. (2012) Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell 21, 121-135
47. Zhou, J., Bi, C., Cheong, L. L., Mahara, S., Liu, S. C., Tay, K. G., Koh, T. L., Yu, Q., and Chng, W. J. (2011) The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118, 2830-2839
48. Sakurai, T., Bilim, V. N., Ugolkov, A. V., Yuuki, K., Tsukigi, M., Motoyama, T., and Tomita, Y. (2012) The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. Biochem. Biophys. Res. Commun. 422, 607-614
49. Alajez, N. M., Shi, W., Hui, A. B., Bruce, J., Lenarduzzi, M., Ito, E., Yue, S., O'Sullivan, B., and Liu, F. F. (2010) Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis. 1, e85